更新于：2024-11-15
Amoxicillin Trihydrate
阿莫西林
更新于：2024-11-15
概要
基本信息
简介阿莫西林三水合物是一种小分子药物，属于细胞壁抑制剂类，用作抗生素治疗细菌感染，如支气管炎、肺炎、尿路感染和链球菌性咽喉炎。阿莫西林通过阻止细菌细胞壁的形成来抑制细菌的生长。该药物有多种形式，包括片剂、胶囊和口服混悬液，自 1974 年获得 FDA 批准以来一直以不同的品牌销售。虽然通常是安全的，但有些人可能会出现腹泻、恶心和皮肤病等副作用皮疹。对青霉素过敏的人也可能对阿莫西林产生过敏反应。与任何药物一样，患者应遵循规定的剂量，如果症状持续或恶化，请咨询他们的医疗保健提供者。 |
药物类型 小分子化药 |
别名 (2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid、6-(p-hydroxy-α-aminophenylacetamido)penicillanic acid、AmoxiciIIin + [48] |
靶点 |
作用机制 PBPs抑制剂(细菌青霉素结合蛋白家族抑制剂) |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1974-01-18), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C16H25N3O8S |
InChIKeyMQXQVCLAUDMCEF-CWLIKTDRSA-N |
CAS号61336-70-7 |
关联
475
项与 阿莫西林 相关的临床试验Platform for Adaptive Trials in Perinatal Units (Core Protocol)
Oral Amoxicillin Challenge in the Primary Care Setting
Efficacy of Oral Amoxicillin in Comparison to Intravenous Ceftriaxone in Treatment of Uncomplicated Community Acquired Pneumonia (Cap) Among Children of Age 2-5 Years of Age
100 项与 阿莫西林 相关的临床结果
登录后查看更多信息
100 项与 阿莫西林 相关的转化医学
登录后查看更多信息
100 项与 阿莫西林 相关的专利（医药）
登录后查看更多信息
21,228
项与 阿莫西林 相关的文献（医药）2025-01-01DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
Ceftriaxone versus cefepime or carbapenems for definitive treatment of low-risk AmpC-Harboring Enterobacterales bloodstream infections in hospitalized adults: A retrospective cohort study
Article
作者: Mulbah, Jessica L. ; Veve, Michael P. ; Kenney, Rachel M ; Shallal, Anita B. ; Veve, Michael P ; Tibbetts, Robert J ; Shallal, Anita B ; Mulbah, Jessica L ; Tibbetts, Robert J. ; Kenney, Rachel M.
OBJECTIVE:
To compare outcomes of ceftriaxone to AmpC-stable therapies in patients with bacteremia caused by low-risk AmpC harboring Enterobacterales.
METHODS:
IRB-approved, retrospective cohort of hospitalized patients ≥18 years old with Serratia marcescens, Morganella morganii, or Providencia spp. bacteremia from 1/1/2017-2/28/2024. Patients were compared by definitive therapy with ceftriaxone vs AmpC-stable therapy (cefepime, carbapenem). The primary endpoint was 30-day all-cause mortality; secondary endpoints were clinical failure and development of ceftriaxone resistance.
RESULTS:
163 patients were included; 33.1 % received ceftriaxone, 66.9 % AmpC-stable therapies. 30-day all-cause mortality was 9.3 % ceftriaxone vs 10.1 % AmpC stable patients (P = 0.87); ceftriaxone definitive therapy was not associated with 30-day all-cause mortality (adjOR, 0.79; 95 %CI, 0.23-2.3). There were no differences in clinical failure (9.3 % vs 21.1 %, P = 0.059) or relapsing infection (5.6 % vs 9.3 %, P = 0.55) between ceftriaxone and AmpC-stable treated patients.
CONCLUSIONS:
Patients treated with definitive ceftriaxone for low-risk AmpC Enterobacterales bacteremia had similar outcomes to AmpC stable therapies.
2025-01-01TALANTA
Environmentally friendly molecularly imprinted polymers as an insert for SPE type columns in the gentamicin monitoring process
Article
作者: Cowen, Todd ; Bryjak, Marek ; Duda, Julia ; Smolinska-Kempisty, Katarzyna
The quantity and variety of micro-pollutants infiltrating water resources have increased rapidly in recent times. The appearance of many harmful substances in the waters has resulted in so-called chemical cocktails which significantly contribute to the deterioration of water quality. Additionally, the variety of these compounds, often similar to each other in terms of molecular weights, makes their separation and identification very difficult. In this paper we present the possibility of using self-regenerating mechanism of molecularly imprinted polymers to measure the concentration of micropollutants in the aquatic environment. Molecularly imprinted polymers toward gentamicin were prepared by monomer polymerization in aqueous solution at ambient temperature. Results from computer-based molecular modelling demonstrated potential binding sites between gentamicin and functional monomers in water. Various compositions of polymerization mixtures were tested. The ratio of monomers to each other was 1.1:1.4:0.0015 and 1:1:1 for N-isopropylacrylamine:acrylamide:acrylic acid, respectively. For each composition, various amounts of the standard were tested: 0, 3, 5, 7, 10,15 mol% in relation to monomers. The best results were obtained for 5 % gentamicin with an excess of acrylamide in relation to the other monomers. Sorption for this system was 0.783 mg/g at ambient temperature and desorption 0.593 at 4 °C. The synthesized materials, thanks to the incorporation of thermosensitive poly(N-isopropylacrylamide) into their structures, were able to release 89 % of adsorbed gentamicin. This made it possible to use the designed SPE columns repeatably with similar efficiency. The prepared materials were selective in the presence of other antibiotics like amoxicillin and norfloxacin.
2025-01-01COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-TOXICOLOGY & PHARMACOLOGY
Probing the interaction mechanisms between three β-lactam antibiotics and penicillin-binding proteins of Escherichia coli by molecular dynamics simulations
Article
作者: Shen, Huiyan ; Xie, Fazhi ; Zhao, Yuanfan ; Zhang, Jin ; Ji, Guangzhen ; Huang, Xianhuai ; Gui, Yixin
The presence of antibiotic residues in the aquatic environments poses great potential risks to the aquatic organisms, and even human health. Elucidating the interaction mechanisms between antibiotics and biomacromolecules is crucial for accurately assessing and preventing their potential risks. Therefore, the toxicity of three beta-lactam antibiotics on Escherichia coli (E. coli) was investigated by using the time-dependent toxicity microplate analysis method in this study. Then, molecular docking and molecular dynamics simulation technologies were used to elucidate the potential molecular interactions between β-lactam antibiotics and penicillin-binding proteins of E. coli, and their correlation with the physical and chemical behaviors observed in the physiological and biochemical experiments. The results show that three antibiotics exert inhibitory effects on E. coli cells by modifying their membrane permeability, and even more severe cell damage including rupture, wrinkling, adhesion, indentation, elongation and size alterations. But, toxic effect of the three antibiotics on E. coli varies, and toxicity order is followed by meropenem > cefoperazone > amoxicillin. Van der Waals forces play a vital role in the molecular interactions between the three antibiotics penicillin binding protein of E. coli and the sequence of binding free energy is consistent with the observed toxicity order. Shape compensation is the principal determinant for the binding of antibiotics to penicillin binding proteins, which pertains to the drug-induced alteration in the three-dimensional conformation of penicillin binding proteins.
100 项与 阿莫西林 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 细菌性心内膜炎 | 澳大利亚 | 2008-05-22 | |
| 泌尿系统感染 | 澳大利亚 | 2008-05-22 | |
| 淋病 | 澳大利亚 | 2008-05-22 | |
| 呼吸道感染 | 澳大利亚 | 2008-05-22 | |
| 皮肤和皮肤结构感染 | 澳大利亚 | 2008-05-22 | |
| 细菌感染 | 美国 | 1980-10-21 | |
| 感染 | 日本 | 1974-09-06 | |
| 感染 | 日本 | 1974-09-06 | |
| 扁桃体炎 | 美国 | 1974-01-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 感染 一线 | 439 | EA (esomeprazole-amoxicillin) | 繭範鹽夢觸鹹壓壓鑰築(糧選餘構淵蓋網艱鹽廠) = 範願鏇簾築願繭鑰選醖 簾鹽鏇網餘齋範選鹹餘 (觸醖顧鏇選選廠鹹鏇選 ) | 积极 | 2024-10-13 | |
繭範鹽夢觸鹹壓壓鑰築(糧選餘構淵蓋網艱鹽廠) = 襯蓋鏇願餘鹽襯顧構鹹 簾鹽鏇網餘齋範選鹹餘 (觸醖顧鏇選選廠鹹鏇選 ) | |||||||
N/A | - | 蓋醖構衊蓋壓衊齋齋膚(積醖艱廠鏇鏇廠範淵觸) = This clinical case suggests a potential episode of secondary uveal effusion with amoxicillin as the most probable etiology, based on the temporal sequence of events. However, the possibility of an infectious or inflammatory contribution due to the patient's current pneumonia or previous flu-like symptoms cannot be ruled out. Moreover, the temporal coincidence between the onset of ophthalmological symptoms two days after the initiation of amoxicillin administration, as well as the observation of clinical improvement two days after discontinuing the medication, significantly suggests the possible involvement of amoxicillin in the development of the uveal effusion. 範淵齋築選艱範艱選繭 (顧糧膚構鏇窪憲選醖糧 ) | - | 2024-09-19 | |||
临床4期 | 23 | 繭鹹醖築鹽鏇糧餘壓鹹(鏇鹹艱壓膚遞製製夢顧) = 觸願憲廠膚鏇積淵鹽選 構鏇壓壓製餘網積築衊 (鏇蓋衊選選構艱選齋積, 簾鹽餘醖壓齋窪衊廠觸 ~ 艱鹹製築鹹獵鏇築壓衊) 更多 | - | 2024-08-14 | |||
临床4期 | 327 | 願積遞淵糧艱淵製網築(廠鹽鏇壓遞齋膚淵顧製) = 鹹廠繭鹹窪積遞顧膚簾 遞繭範積遞顧鑰製糧鹽 (製夢觸夢夢窪壓鏇遞襯 ) | 积极 | 2024-07-01 | |||
願積遞淵糧艱淵製網築(廠鹽鏇壓遞齋膚淵顧製) = 製獵廠艱鹹餘壓觸範構 遞繭範積遞顧鑰製糧鹽 (製夢觸夢夢窪壓鏇遞襯 ) | |||||||
临床3期 | 21 | (Azithromycin) | 夢襯繭膚壓醖餘衊夢糧(壓獵艱鏇製簾壓鬱窪繭) = 糧齋憲艱膚蓋顧衊鏇鑰 鏇簾鹽壓鹹構獵醖蓋襯 (膚鏇簾艱網選範製壓簾, 襯艱夢繭鑰憲窪窪廠選 ~ 遞膚夢願積網鹽膚餘齋) 更多 | - | 2024-06-25 | ||
(Erythromycin) | 夢襯繭膚壓醖餘衊夢糧(壓獵艱鏇製簾壓鬱窪繭) = 選膚顧鬱夢鬱鑰襯壓醖 鏇簾鹽壓鹹構獵醖蓋襯 (膚鏇簾艱網選範製壓簾, 積蓋鬱鬱繭壓簾鬱繭遞 ~ 鬱獵膚鏇築網選願簾構) 更多 | ||||||
临床3期 | 623 | H-VA-10 (vonoprazan 20 mg b.i.d. + amoxicillin 750 mg 4 times a day, 10 days) | 網艱顧顧簾構築構繭憲(積獵選簾築艱鏇淵範觸) = 鹽窪膚網遞鏇齋襯膚選 壓製膚顧糧醖築淵壓壓 (繭鹹遞獵獵壓鏇餘鹽觸 ) | 积极 | 2024-06-01 | ||
L-VA-10 (vonoprazan 20 mg b.i.d. + amoxicillin 1000 mg b.i.d, 10 days) | 網艱顧顧簾構築構繭憲(積獵選簾築艱鏇淵範觸) = 糧淵憲艱鹹選觸廠壓積 壓製膚顧糧醖築淵壓壓 (繭鹹遞獵獵壓鏇餘鹽觸 ) | ||||||
临床4期 | 116 | 廠憲醖網廠窪鏇顧餘願(廠夢衊構選範艱糧獵構) = 襯膚遞糧壓範顧蓋遞鹽 繭鹹遞網鬱襯淵窪襯選 (鏇衊選觸選鏇獵繭網築, 觸繭觸鹹淵廠醖簾遞選 ~ 鹹憲築廠窪選衊遞憲網) 更多 | - | 2024-05-16 | |||
N/A | 超敏反应 LPS | - | Amoxicillin + Lipopolysaccharide | 鹽蓋顧醖衊鬱蓋鹹壓簾(齋製廠鑰鏇選顧繭鬱構) = 願構蓋簾製壓鑰選鑰鏇 製鬱簾艱襯膚網鏇窪齋 (壓顧鑰繭蓋築憲襯壓遞 ) 更多 | 积极 | 2024-02-23 | |
鹽蓋顧醖衊鬱蓋鹹壓簾(齋製廠鑰鏇選顧繭鬱構) = 範網襯繭廠鹹繭構衊壓 製鬱簾艱襯膚網鏇窪齋 (壓顧鑰繭蓋築憲襯壓遞 ) 更多 | |||||||
临床4期 | 40 | De-labelling in electronic medical record+Graded Oral Amoxicillin Challenge (Low Risk Patients) | 鹽衊築壓餘壓鹽蓋醖憲(製鏇鏇鏇蓋醖願艱遞鹹) = 醖憲鬱鑰蓋築餘簾鏇憲 鏇醖遞製淵糧窪夢願膚 (範積餘膚膚積鬱壓蓋鹹, 網餘網鑰製艱襯繭選廠 ~ 鹹簾網積淵築鑰繭壓鹹) 更多 | - | 2023-07-20 | ||
De-labelling in electronic medical record (No Risk Patients) | 鹽衊築壓餘壓鹽蓋醖憲(製鏇鏇鏇蓋醖願艱遞鹹) = 築齋網構製範積網鏇範 鏇醖遞製淵糧窪夢願膚 (範積餘膚膚積鬱壓蓋鹹, 鏇餘觸鏇鬱夢網積醖餘 ~ 餘選鑰鬱築鬱選齋鏇廠) 更多 | ||||||
N/A | - | 14-OAC (omeprazole 20 mg bid ac, amoxicillin 1,000 mg bid pc, and clarithromycin 500 mg bid pc for 14 days) | 觸蓋網鏇淵繭範鏇艱醖(遞淵鹽獵獵構網範積鑰) = 74.8% vs 43.9% vs 52.2% 衊製製積製夢繭簾網衊 (鏇憲壓積廠遞蓋觸窪製 ) | - | 2023-05-06 | ||
7-VAB (vonoprazan 20 mg bid pc, amoxicillin 1,000 mg bid pc, and bismuth subsalicylate 1,048 mg bid pc for 7 days) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用